MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Zacks11-08

Myriad Genetics, Inc. MYGN reported third-quarter 2024 adjusted earnings of 6 cents per share, which beat the Zacks Consensus Estimate of 2 cents. The company reported a loss of 3 cents per share in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481010901?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gl_19R8DekmvzA3Zg3Yozg--~B/aD0zOTQ7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0ebf144352a95b22dfed01b36b0e82c5","is_english":true,"pubTime":"2024-11-08 21:28","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481010901","market":"us","top_or_hot":-1,"title":"MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View","media":"Zacks","content":"<div>\n<p>Myriad Genetics, Inc. MYGN reported third-quarter 2024 adjusted earnings of 6 cents per share, which beat the Zacks Consensus Estimate of 2 cents. The company reported a loss of 3 cents per share in ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mygn-beats-q3-earnings-revenues-132800465.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mygn-beats-q3-earnings-revenues-132800465.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Myriad Genetics, Inc. MYGN reported third-quarter 2024 adjusted earnings of 6 cents per share, which beat the Zacks Consensus Estimate of 2 cents. The company reported a loss of 3 cents per share in ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mygn-beats-q3-earnings-revenues-132800465.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"https://finance.yahoo.com/news/mygn-beats-q3-earnings-revenues-132800465.html","article_id":"2481010901","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gl_19R8DekmvzA3Zg3Yozg--~B/aD0zOTQ7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0ebf144352a95b22dfed01b36b0e82c5"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481010901","pubTimestamp":1731072480,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Myriad Genetics, Inc. MYGN reported third-quarter 2024 adjusted earnings of 6 cents per share, which beat the Zacks Consensus Estimate of 2 cents. The company reported a loss of 3 cents per share in the year-ago quarter.Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, MYGN’s share price remained unchanged at $17.64 in after-market trading yesterday.Myriad Genetics exited the third quarter of 2024 with cash and cash equivalents of $99.9 million compared with $92.4 million at the end of the second quarter.Myriad Genetics, Inc. Price, Consensus and EPS Surprise. Myriad Genetics, Inc. price-consensus-eps-surprise-chart | Myriad Genetics, Inc. Quote. Myriad Genetics delivered better-than-expected earnings and revenues in the third quarter of 2024. The strong performance was driven by robust growth across","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传","DGX":"奎斯特诊疗"},"translate_title":"MYGN第三季度盈利和收入好于预期，上调24年每股收益预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1,"DGX":0.9},"content_text":"Myriad Genetics, Inc. MYGN reported third-quarter 2024 adjusted earnings of 6 cents per share, which beat the Zacks Consensus Estimate of 2 cents. The company reported a loss of 3 cents per share in the year-ago quarter.\nAdjusted earnings exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nFollowing the earnings announcement, MYGN’s share price remained unchanged at $17.64 in after-market trading yesterday.\nMYGN’s Q3 Revenues\nTotal revenues rose 11% year over year to $213.3 million. The figure topped the Zacks Consensus Estimate by 1.7%. Testing volumes increased 6% year over year.\nMYGN’s Q3 Revenues in Detail\nHereditary Cancer testing revenues rose 5% year over year to $90.5 million.\nPharmacogenomics testing revenues totaled $47.7 million, up 34% year over year.\nTumor Profiling testing revenues rose 5% year over year to $31.6 million.\nPrenatal testing revenues came in at $43.5 million, up 10% year over year.\nMargin Trends\nThe gross margin expanded 24 basis points (bps) to 70.2%.\nResearch and development expenses rose 18.8% year over year to $28.5 million. SG&A expenses increased 2.2% to $139.1 million in the reported quarter.\nThe adjusted operating loss was $17.8 million compared with a loss of $25.8 million in the year-ago quarter.\nFinancial Position\nMyriad Genetics exited the third quarter of 2024 with cash and cash equivalents of $99.9 million compared with $92.4 million at the end of the second quarter.\nLong-term debt amounted to $39 million compared with $38.8 million at the end of the second quarter.\nThe cumulative net cash used in operating activities at the end of the reported quarter was $15.3 million compared with $56.2 million in the year-ago period.\nMYGN’s 2024 Guidance\nMyriad Genetics provided an updated 2024 guidance.\nThe company now expects revenues to be in the range of $837-$843 million (earlier $835-$845 million), suggesting 11-12% growth over the prior-year level. The Zacks Consensus Estimate for the same is pegged at $850 million.\nAdjusted earnings per share (EPS) are now expected to be in the range of 12-14 cents (up from the earlier projection of 8-12 cents). The Zacks Consensus Estimate for the same is pegged at 10 cents.\nMyriad Genetics, Inc. Price, Consensus and EPS Surprise\n\n\nMyriad Genetics, Inc. price-consensus-eps-surprise-chart | Myriad Genetics, Inc. Quote\n\nOur Take\nMyriad Genetics delivered better-than-expected earnings and revenues in the third quarter of 2024. The strong performance was driven by robust growth across all the product portfolios of the company. Average revenue per test improved across the product portfolio, benefiting from expanded coverage and ongoing efforts in revenue cycle management.\nNotable highlights in the quarter include establishment of a number of additional research collaborations with leading cancer research institutions, including The University of Texas MD Anderson Cancer Center and the National Cancer Center Hospital East in Japan, regarding the use of the company's Precise MRD test for breast cancer patients. Also, Myriad Genetics expanded payor coverage for its several products, including GeneSight. \nThe raised EPS guidance for the full year instill optimism among investors. On the flip side, the company’s operating loss during the quarter adds to the worry. \nMYGN’s Zacks Rank & Key Picks\nMYGN currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the broader medical space are Phibro Animal Health PAHC, Quest Diagnostics DGX and HealthEquity HQY.\nPhibro Animal Health reported fourth-quarter fiscal 2024 adjusted earnings of 41 cents per share, which topped the Zacks Consensus Estimate by 20.6%. Revenues of $273.2 million beat the Zacks Consensus Estimate by 4.1%. PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nPAHC’s fiscal 2025 earnings are expected to surge 31.9% compared with the industry’s 11.6% growth. The company’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 4.1%.\nQuest Diagnostics reported third-quarter 2024 adjusted earnings of $2.30 per share, which topped the Zacks Consensus Estimate by 1.8%. Revenues of $2.49 billion beat the consensus mark by 3.4%. \nDGX carries a Zacks Rank #2 (Buy) at present. DGX’s 2024 earnings are expected to surge 2.1% year over year. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.3%.\nHealthEquity, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2025 adjusted earnings of 86 cents per share, which surpassed the Zacks Consensus Estimate by 22.9%. Revenues of $299.9 million topped the Zacks Consensus Estimate by 5.4%.\nHQY has an estimated long-term earnings growth rate of 28.2% compared with the industry’s 13.4%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.8%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nQuest Diagnostics Incorporated (DGX) : Free Stock Analysis Report\nMyriad Genetics, Inc. (MYGN) : Free Stock Analysis Report\nPhibro Animal Health Corporation (PAHC) : Free Stock Analysis Report\nHealthEquity, Inc. (HQY) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481010901"}